GlassScriptPhysician profile
Christopher F Cukrowski
NPI 1912991845
$892.72
in general payments reported to CMS, 2019-2025
14 companies · $55.68 in 2025
The $55.68 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2021: $91.54 · 2022: $44.09 · 2023: $353 · 2024: $201 · 2025: $55.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $294.46 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Carl Zeiss Meditec USA, INC. | $276.00 | 2023 | Veracity Surgical, Lumera 700, Iolmaster 700 |
| Abbvie INC. | $47.77 | 2024 | |
| Amgen INC. | $45.89 | 2024 | Tepezza |
| Glaxosmithkline, LLC. | $34.58 | 2021-2022 | |
| Alcon Vision LLC | $31.72 | 2021-2023 | Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $30.00 | 2019 | |
| Astellas Pharma US INC | $25.74 | 2023 | |
| Novartis Pharmaceuticals Corporation | $23.19 | 2022 | |
| Dompe US, INC. | $19.62 | 2025 | Oxervate |
| New World Medical,INC. | $18.99 | 2025 | Via360, Streamline, Kahook Dual Blade |
| Sun Pharmaceutical Industries INC. | $17.07 | 2025 | |
| Allergan, INC. | $13.88 | 2021 | |
| Horizon Therapeutics Plc | $13.81 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cukrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.